- ►cardiobarbanza.com [PDF] DM Nathan, JB Buse, MB Davidson, E Ferrannini, RR … - Diabetologia, 2009 - Springer Page 1. CONSENSUS STATEMENT UPDATE Medical management of
hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation
and adjustment of therapy A consensus statement from the American ... Cited by 1054 - Related articles - BL Direct - All 92 versions
RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study at
82 US sites was performed with 336 randomized patients. In all, 272 patients completed the
study. The intent-to-treat population baseline was 53 ± 10 years with BMI of 34.2 ± 5.9 ... Cited by 644 - Related articles - All 6 versions
DM Kendall, MC Riddle, J Rosenstock, D Zhuang, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg), −0.6 ±
0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs. placebo), yielding placebo-adjusted
reductions of −1.0% (10 μg) and −0.8% (5 μg). In the evaluable population, exenatide- ... Cited by 548 - Related articles - All 11 versions
DJ Drucker, MA Nauck - The Lancet, 2006 - Elsevier Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and
suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite and food
intake. Therapeutic approaches for enhancing incretin action include ... Cited by 416 - Related articles - All 10 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal …, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control (defined as hemoglobin
A1c level ranging from 7.0% to 10.0%) despite combination metformin and sulfonylurea
therapy. Intervention: Exenatide, 10 g twice daily, or insulin glargine, 1 daily dose titrated ... Cited by 332 - Related articles - BL Direct - All 7 versions
- ►wanfang.gov.tw [DOC] RE Amori, J Lau, AG Pittas - Jama, 2007 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do to make
your experience on this site better. ... Add to CiteULike Add to Connotea Add to ... Cited by 248 - Related articles - BL Direct - All 8 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & …, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age 56 ± 10
years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ± 1.0% (mean ± SD)]. Reduction
in A1C from baseline to week 30 [-0.9 ± 0.1% (mean ± SE)] was sustained to week 82 ... Cited by 174 - Related articles - BL Direct - All 6 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ... Cited by 179 - Related articles - All 25 versions
- ►januvia.se [PDF] I Raz, M Hanefeld, L Xu, C Caria, D Williams-Herman, … - Diabetologia, 2006 - Springer Abstract Aims/hypothesis The aim of this study was to assess the efficacy and safety of sitagliptin
(MK-0431) as mono- therapy in patients with type 2 diabetes mellitus and inadequate glycaemic
control (HbA 1c Q7% and e10%) on exercise and diet. Methods A total of 521 patients ... Cited by 167 - Related articles - All 5 versions
M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2006 - journals.prous.com Contributing Editors: P. Cole, C. Orellana, JA Vallès, RM a . Antonijoan, KP Mohana Priya,
M. Priya, V. Renuga, R. Sree Lekha, B. Priya, A. Tomillero, G. Krithiga and E. Banu Rekha. Cited by 148 - Related articles - All 9 versions
